Foundry Healthcare Return on Assets Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 26.49% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 14.53% |
3MRK | MERCK & CO INC | Healthcare | $314.90B | 7.51% |
4TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $197.88B | 4.72% |
5AMGN | AMGEN INC | Healthcare | $197.69B | 4.72% |
6GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 3.98% |
7BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 2.96% |
8VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 2.94% |
9SYK | STRYKER CORP | Healthcare | $122.63B | 2.93% |
10ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 2.92% |
11MCK | MCKESSON CORP | Healthcare | $101.14B | 2.41% |
12HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 1.96% |
13REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 1.69% |
14BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 1.56% |
15EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 1.18% |
16IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.07% |
17A | AGILENT TECHNOLOGIES INC | Healthcare | $37.13B | 0.89% |
18ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.85% |
19ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.83% |
20ZTS | ZOETIS INC | Healthcare | $32.10B | 0.77% |
21VEEV | VEEVA SYSTEMS INC | Healthcare | $31.74B | 0.76% |
22DXCM | DEXCOM INC | Healthcare | $29.58B | 0.71% |
23RMD | RESMED INC | Healthcare | $28.86B | 0.69% |
24ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.67% |
25MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.63% |
26WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $25.31B | 0.60% |
27INCY | INCYTE CORP | Healthcare | $23.42B | 0.56% |
28DGX | QUEST DIAGNOSTICS INC | Healthcare | $23.32B | 0.56% |
29UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.54% |
30STE | STERIS PLC | Healthcare | $21.26B | 0.51% |
31NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.41% |
32MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.37% |
33SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.34% |
34EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.34% |
35ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.30% |
36PEN | PENUMBRA INC | Healthcare | $12.52B | 0.30% |
37PODD | INSULET CORP | Healthcare | $11.36B | 0.27% |
38EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.27% |
39KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.25% |
40GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.25% |
41ENSG | ENSIGN GROUP INC | Healthcare | $10.01B | 0.24% |
42CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.23% |
43HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.22% |
44UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.22% |
45ATR | APTARGROUP INC | Healthcare | $8.46B | 0.20% |
46TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.20% |
47HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.19% |
48LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.17% |
49CHE | CHEMED CORP | Healthcare | $6.77B | 0.16% |
50LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.15% |
51KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.12% |
52VCYT | VERACYTE INC | Healthcare | $4.72B | 0.11% |
53ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.10% |
54CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.10% |
55DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.09% |
56CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.09% |
57NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.09% |
58OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.08% |
59GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.06% |
60TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.06% |
61PGNY | PROGYNY INC | Healthcare | $2.50B | 0.06% |
62LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.06% |
63MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.05% |
64ADUS | ADDUS HOMECARE CORP | Healthcare | $2.14B | 0.05% |
65AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.05% |
66AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.05% |
67ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.05% |
68HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.05% |
69UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.04% |
70ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.04% |
71HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.04% |
72INVA | INNOVIVA INC | Healthcare | $1.60B | 0.04% |
73INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.03% |
74PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.03% |
75IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.03% |
76NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.03% |
77TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.02% |
78ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.02% |
79RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.02% |
80OMER | OMEROS CORP | Healthcare | $701M | 0.02% |
81CRMD | CORMEDIX INC | Healthcare | $661M | 0.02% |
82TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.02% |
83XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.01% |
84NRC | NRC HEALTH | Healthcare | $491M | 0.01% |
85VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.01% |
86PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
87ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.01% |
88ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
89QTTB | Q32 BIO INC | Healthcare | $255M | 0.01% |
90SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
91UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.01% |
92AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
93PDEX | PRO DEX INC | Healthcare | $183M | 0.00% |
94INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
95LNSR | LENSAR INC | Healthcare | $70M | 0.00% |
96SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $4.19T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 62% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 96 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual66.5%Margin-8.5%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual26.5%Margin-1.5%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 96 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 24.6% | -24.1% |
| 3 yearsp.a. | 9.5% | -15.1% |
| 5 yearsp.a. | 5.9% | 1.3% |
| 10 yearsp.a. | 10.3% | 1.7% |
| Since inceptionp.a. | 8.1% | -7.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 2.5% | -12.9% |
| 2025 | 18.4% | -26.3% |
| 2024 | 4.3% | 16.4% |
| 2023 | 3.1% | -29.9% |
| 2022 | -4.6% | 47.0% |
| 2021 | 27.8% | 87.6% |
| 2020 | 17.8% | -17.0% |
| 2019 | 18.2% | -10.4% |
| 2018 | 7.1% | 23.1% |
| 2017 | 21.2% | -4.2% |
| 2016 | 0.1% | 16.6% |
| 2015 | 3.9% | 4.0% |
| 2014 | 23.8% | -7.2% |
| 2013 | 41.1% | -1.6% |
| 2012 | 19.2% | -14.4% |
| 2011 | 13.4% | 19.1% |
| 2010 | 4.6% | -9.2% |
| 2009 | 21.3% | -0.8% |
| 2008 | -17.5% | 8.1% |
| 2007 | 6.2% | 13.2% |
| 2006 | 6.7% | 2.2% |
| 2005 | 2.7% | 6.0% |
| 2004 | 4.7% | -7.6% |
| 2003 | 8.3% | -40.9% |
| 2002 | -20.7% | 62.6% |
| 2001 | -15.1% | -4.9% |
| 2000 | 35.9% | -87.7% |
| 1999 | -3.4% | -40.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Return on Assets Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Return on Assets signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.